Fig 1.
Study period for patients initiating apixaban, dabigatran, rivaroxaban, and warfarin. AF: atrial fibrillation.
Fig 2.
Study population flow chart with inclusion and exclusion criteria used to select 45,361 patients. NOAC: non-vitamin K antagonist oral anticoagulant; VTE: venous thromboembolism.
Table 1.
Baseline patient characteristics and treatment follow-up period.
Fig 3.
Cumulative incidence of discontinuation among newly anticoagulated non-valvular atrial fibrillation patients.
(Upper panel) Cumulative incidence of discontinuation during the follow-up period. The unadjusted cumulative incidence of discontinuation was lower among patients initiated on apixaban compared to patients inititated on other oral anticoagulants. (Lower panel) The number of patients at risk for discontinuation at varying points during the follow-up.
Table 2.
Adjusted hazard ratios of discontinuation.